Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in HR-Positive, HER2-Negative Patients with Advanced Breast Cancer After First-Line ChemotherapyOncologist 2020 Nov 27;[EPub Ahead of Print], F Xu, Q Zheng, W Xia, Q Ouyang, D Pang, Z Yuan, Y Shi, R Peng, Q Lu, S Wang
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.